A now-defunct collaboration on diabetes drugs meant more to Amylin than to the much larger Lilly, an analyst said.
(Darron Cummings/Associated Press/File 2011)
Lilly and Amylin end partnership, lawsuit
A now-defunct collaboration on diabetes drugs meant more to Amylin than to the much larger Lilly, an analyst said.
(Darron Cummings/Associated Press/File 2011)
Drug makers Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said Tuesday that they will end their long-standing collaboration to develop diabetes drugs, an announcement that sent Amylin shares tumbling.
For more from BostonGlobe.com, sign up or log in below
To continue, please sign up or log in to BostonGlobe.com
Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com
Sign up
Unlimited Access to BostonGlobe.com for 4 weeks for only 99¢.
Are you a Boston Globe home delivery subscriber?
Get FREE access as part of your print subscription.
BostonGlobe.com subscriber
Click to continue reading this article or to log in to BostonGlobe.com.
